| Literature DB >> 27485430 |
Julia Metzger1, Sophia Pfahler2, Ottmar Distl2.
Abstract
BACKGROUND: The Lundehund is a highly specialized breed characterized by a unique flexibility of the joints and polydactyly in all four limbs. The extremely small population size and high inbreeding has promoted a high frequency of diseased dogs affected by the Lundehund syndrome (LS), a severe gastro-enteropathic disease.Entities:
Keywords: LEPREL1; Lundehund syndrome; Runs of homozygosity
Mesh:
Year: 2016 PMID: 27485430 PMCID: PMC4971756 DOI: 10.1186/s12864-016-2844-6
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1Polydactyly in the Lundehund. Polydactyly with six toes at all four limbs is a characteristic trait in the Lundehund
Fig. 2Clinical picture of Lundehund syndrome (LS). A five year old Lundehund with severe signs of LS is shown. Persistent diarrhea, vomiting and ascites resulted in marked weight and hair loss. The dog had to be euthanized due to poor prognosis and unresponsive therapy
Fig. 3Genome-wide association analysis (GWAS) for Lundehund syndrome (LS). a The Manhattan-plot of the -log10 P-values shows a highly significant peak on canine chromosome (CFA) 34 in the region of 23,373,982-24,488,983 bp (CanFam 3.0). b Observed versus expected -log10 P-values (Q-Q plot) reveal 31 SNPs with highly significant -log10 P-values
Statistical overrepresentation test for biological processes. All human orthologues derived from ROH detection were analyzed for an enrichment of genes involved in specific processes using PANTHER tools. The number of detected genes in ROH regions in 500-SNP windows and Gene Ontology (GO) terms are shown for Bonferroni corrected significant P-values <0.05
| Number of reference genes (Homo sapiens) | ROH regions in LS-affected: expected | Bonferroni corrected P-value for multiple testing | Private ROH regions in LS-affected: expected | Bonferroni corrected P-value for multiple testing | Private ROH regions in LS-unaffected: expected | Bonferroni corrected | Lundehund consensus ROH regions: expected | Bonferroni corrected P-value for multiple testing | |
|---|---|---|---|---|---|---|---|---|---|
| Single-organism cellular process (GO:0044763) | 11415 | ─ | ─ | ─ | ─ | ─ | ─ | 480.42 | 1.03E-06 |
| Single-organism process (GO:0044699) | 12755 | ─ | ─ | ─ | ─ | ─ | ─ | 536.82 | 5.36E-06 |
| Cellular process (GO:0009987) | 14147 | 1714.55 | 3.37E-05 | ─ | ─ | ─ | ─ | 595.41 | 4.70E-07 |
| Biological process (GO:0008150) | 16542 | ─ | ─ | ─ | ─ | ─ | ─ | 696.2 | 1.02E-04 |
| Generation of neurons (GO:0048699) | 1551 | ─ | ─ | ─ | ─ | 61.18 | 1.61E-02 | ─ | ─ |
| Neurogenesis (GO:0022008) | 1628 | ─ | ─ | ─ | ─ | 64.22 | 2.46E-02 | ─ | ─ |
| Cellular component organization or biogenesis (GO:0071840) | 5188 | ─ | ─ | ─ | ─ | 204.64 | 1.47E-02 | ─ | ─ |
| Cellular protein modification process (GO:0006464) | 1317 | 336.62 | 1.15E-03 | ─ | ─ | ─ | ─ | ─ | ─ |
| Protein metabolic process (GO:0019538) | 2692 | 688.07 | 2.95E-04 | ─ | ─ | ─ | ─ | ─ | ─ |
| Metabolic process (GO:0008152) | 8247 | 2107.91 | 7.09E-04 | ─ | ─ | ─ | ─ | ─ | ─ |
| Primary metabolic process (GO:0044238) | 6825 | 1744.45 | 1.39E-02 | ─ | ─ | ─ | ─ | ─ | ─ |
| Transcription, DNA-dependent (GO:0006351) | 1941 | 496.11 | 4.71E-03 | ─ | ─ | ─ | ─ | ─ | ─ |
| Regulation of nucleobase-containing compound metabolic process (GO:0019219) | 1700 | 434.52 | 1.03E-02 | ─ | ─ | ─ | ─ | ─ | ─ |
Filtered variants from whole-genome analysis. Variants with predicted high or moderate effects and a homozygous mutant genotype exclusively found in the LS-affected pool as well as a heterozygous or homozygous wild-type genotype in the LS-unaffected pool are shown. All five reference dogs of four different breeds do not show the mutant genotype. Potential functional effects of these variants were predicted using SIFT and PolyPhen
| CFA | Position | Base change | Amino acid change | Consequence | Genotype (LS-affected Lunde-hund pool) | Genotype (LS-unaffected Lunde-hund pool) | Genotype (5 reference dogs) | Gene (transcript) | SIFT | PolyPhen-2 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 13398018 | T>G | T>P/ S>R | missense variant | 1/1 | 0/0 | 0/0 | ENSCAFG00000031329 (novel gene; (ENSCAFT00000043665) and ENSCAFG00000030129 (novel gene; ENSCAFT00000048679) | tolerated (0.07)/ deleterious (0.02) | benign (0.074)/- |
| 1 | 111903572 | A>G | T>A | missense variant | 1/1 | 0/1 | 0/0 | CEACAM1 (ENSCAFT00000007749/ ENSCAFT00000046087/ ENSCAFT00000022623/ ENSCAFT00000047331/ ENSCAFT00000049292) | tolerated (0.08/ 0.13/ 0.2/ 0.21/ 0.2) | benign (0.00)/ benign (0.310)/ possibly damaging (0.659)/ possibly damaging (0.605)/ benign (0.250) |
| 3 | 56483857 | G>T | P>T | missense variant | 1/1 | 0/1 | 0/0 | IL16 (ENSCAFT00000021964) | tolerated (0.59) | benign (0.310) |
| 3 | 62265062 | A>T | F>I | missense variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000017475 (novel gene; ENSCAFT00000027691) | deleterious (0.01) | possibly damaging (0.614) |
| 5 | 16233038 | G>T | L>M | missense variant | 1/1 | 0/1 | 0/0 | CEP164 (ENSCAFT00000020686) | deleterious (0.02) | probably damaging (0.996) |
| 6 | 67204999 | C>T | R>Q | non coding transcript variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000005648 (novel gene; ENSCAFT00000009086) | - | - |
| 6 | 67205308 | A>C | Y>* (stop codon) | non coding transcript variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000005648 (novel gene; ENSCAFT00000009086) | - | - |
| 6 | 67205754 | G>A | R>* (stop codon) | non coding transcript variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000005648 (novel gene; ENSCAFT00000009086) | - | - |
| 6 | 67205959 | A>G | L>P | non coding transcript variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000005648 (novel gene; ENSCAFT00000009086) | - | - |
| 6 | 67205966 | T>G | T>P | non coding transcript variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000005648 (novel gene; ENSCAFT00000009086) | - | - |
| 7 | 2590167 | G>A | S>N | missense variant | 1/1 | 0/1 | 0/0 | KIF14 (ENSCAFT00000017720) | tolerated (0.21) | benign (0.002) |
| 7 | 4169250 | A>T | F>Y | missense variant | 1/1 | 0/1 | 0/0 | PTPRC (ENSCAFT00000017964/ ENSCAFT00000017955) | tolerated (0.3/ 0.31) | benign (0.023/ |
| 8 | 22616300 | C>T | P>L | missense variant | 1/1 | 0/1 | 0/0 | FANCM (ENSCAFT00000046644/ ENSCAFT00000022327/ ENSCAFT00000048988) | tolerated (0.42/ 0.34/ 0.42) | benign (0.009/ 0.009/ 0.004 ) |
| 8 | 47544408 | G>A | G>R | missense variant | 1/1 | 0/1 | 0/0 | VRTN (ENSCAFT00000026784) | tolerated (0.56) | possibly damaging (0.560) |
| 8 | 73685892 | C>G | Q>H | missense variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000029996 (novel gene; ENSCAFT00000049952) | deleterious (0) | benign (0.152) |
| 8 | 73685923 | C>G | W>S | missense variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000029996 (novel gene; ENSCAFT00000049952) | deleterious (0) | probably damaging (1.000) |
| 8 | 73685927 | T>G | S>R | missense variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000029996 (novel gene; ENSCAFT00000049952) | tolerated (0.21) | probably damaging (0.963) |
| 9 | 37739213 | C>T | R>W | missense variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000032731 (novel gene; ENSCAFT00000047013) | tolerated (0.07) | probably damaging (0.998) |
| 9 | 51227945 | T>C | H>R | missense variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000019863 (novel gene; ENSCAFT00000031603) | deleterious (0) | possibly damaging (0.898) |
| 10 | 36330685 | C>T | A>V | missense variant | 1/1 | 0/1 | 0/0 | FAM32A (ENSCAFT00000003279) | tolerated (0.16) | benign (0.328) |
| 11 | 67454670 | A>C | S>R | missense variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000028946 | tolerated (0.33) | - |
| 12 | 40430108-40430109 | A>AGG | R47fs | frameshift variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000030790 (novel gene; ENSCAFT00000045206) | - | - |
| 12 | 52354031 | A>G | F>S | missense variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000030881 (novel gene; | deleterious (0.01) | - |
| 12 | 52354041 | G>A | L>F | missense variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000030881 (novel gene; | deleterious (0.02) | - |
| 14 | 16187782 | T>G | I>M | missense variant | 1/1 | 0/1 | 0/0 | CFAP69 (ENSCAFT00000002973) | tolerated (0.23) | possibly damaging (0.648) |
| 14 | 22993351 | A>T | C>S | missense variant | 1/1 | 0/1 | 0/0 | COL28A1 (ENSCAFT00000044570) | deleterious (0) | probably damaging (1.000) |
| 18 | 39577830 | C>T | A>V | missense variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000030998 (novel gene; ENSCAFT00000047197) | tolerated (1) | benign (0.000) |
| 20 | 54722514 | T>C | I>M | missense variant | 1/1 | 0/1 | 0/0 | KDM4B (ENSCAFT00000030040) | tolerated (0.7) | possibly damaging (0.728) |
| 27 | 2322565 | C>T | R>C | missense variant | 1/1 | 0/1 | 0/0 | KRT3 (ENSCAFT00000011634) | deleterious (0.03) | possibly damaging (0.942) |
| 28 | 31706107 | A>C | N>T | missense variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000012412 (novel gene; (ENSCAFT00000019700) | tolerated (0.78) | benign (0.000) |
| 32 | 21555092 | C>T | D>N | missense variant | 1/1 | 0/1 | 0/0 | TRMT10A (ENSCAFT00000016732) | tolerated (0.31) | probably damaging (0.997) |
| 34 | 22046092 | C>G | E>Q | missense variant | 1/1 | 0/1 | 0/0 | LEPREL1 (ENSCAFT00000022188) | tolerated (0.43) | possibly damaging (0.945) |
| X | 96702059 | A>G | R>G | missense variant | 1/1 | 0/1 | 0/0 | ENSCAFG00000029138 (novel gene; ENSCAFT00000044717) | tolerated (0.41) | benign (0.001) |
* is the official HGVS-symbol for a stop codon
Genotypic distribution of candidate SNPs for LS in Lundehund dogs. Chi-square test results are shown for the four candidate SNPs chosen from filtering analysis for mutations predicted to have high or moderate effects. Genotypes are assigned to Lundehund without signs of LS (0), LS-affected Lundehund (1) and LS-suspicious dogs (1 susp.) due to clinical signs
| CFA | Gene | Polymorphism | Chi-Square genotype (Probability) | Chi-Square allele (Probability) | Chi-Square trend (Probability) | LS status affected (1) or unaffected (0) | Genotype | Genotype | Genotype |
|---|---|---|---|---|---|---|---|---|---|
| 34 |
| LEPREL1:g.139212C>G | 6.807 ( | 4.959 ( | 4.293 ( | 0 | 1 (2.78) | 7 (19.44) | 7 (19.44) |
| 1 | 0 (0.00) | 0 (0.00) | 15 (41.70) | ||||||
| 1 (susp.) | 1 (2.78) | 2 (5.56) | 3 (8.34) | ||||||
| 5 |
| CEP164:g.57380G>T | 6.264 ( | 4.538 ( | 4.412 ( | 0 | 4 (11.43) | 6 (17.14) | 5 (14.29) |
| 1 | 0 (0.00) | 7 (19.46) | 7 (19.46) | ||||||
| 1 (susp.) | 0 (0.00) | 2 (5.56) | 4 (11.12) | ||||||
| 14 |
| COL28A1:g.159951T>A | 0.614 ( | 0.019 ( | 0.021 ( | 0 | 3 (8.57) | 7 (20.00) | 5 (14.29) |
| 1 | 2 (5.72) | 8 (22.80) | 4 (11.44) | ||||||
| 1 (susp.) | 1 (2.86) | 4 (11.44) | 1 (2.86) | ||||||
| 27 |
| KRT3:g.2584C>T | 3.379 ( | 2.483 ( | 2.146 ( | 0 | 3 (8.33) | 8 (22.22) | 4 (11.11) |
| 1 | 3 (8.33) | 4 (11.12) | 8 (22.22) | ||||||
| 1 (susp.) | 0 (0.00) | 2 (5.56) | 4 (11.12) |
Chi-square test for Lundehund dogs and seventeen different breeds. Other breeds are used as controls for Lundehund-specific LS. The test results are shown for the four candidate SNPs chosen from filtering analysis for mutations predicted to have high or moderate effects
| CFA | Gene | Polymorphism | Chi-Square genotype (Probability) | Chi-Square allele (Probability) | Chi-Square trend (Probability) |
|---|---|---|---|---|---|
| 34 |
| LEPREL1:g.139212C>G | 132.735 ( | 238.686 ( | 130.861 ( |
| 5 |
| CEP164:g.57380G>T | 83.884 ( | 120.165 ( | 83.716 ( |
| 14 |
| COL28A1:g.159951T>A | 101.034 ( | 116.566 ( | 79.531 ( |
| 27 |
| KRT3:g.2584C>T | 3.379 ( | 2.483 ( | 2.146 ( |